KRAS and lung cancer: This work has culminated in a phase I trial of lead compound AMG 510 (NCT03600883) which produced partial responses in 50% of evaluable patients with KRAS G12C-mutant non–small cell lung cancer, and stable disease in the majority of patients with colorectal or appendiceal cancer [54].